<DOC>
	<DOCNO>NCT01252290</DOCNO>
	<brief_summary>This study design gather information prescription drug Lovaza™ contain omega-3 fatty acid , affect blood tissue risk biomarkers breast cancer . This drug currently approve FDA reduce blood level triglyceride .</brief_summary>
	<brief_title>Breast Cancer Risk Biomarkers Postmenopausal Women</brief_title>
	<detailed_description>The central hypothesis 6 month administration high dose omega-3 fatty acid ester [ eicosapentaenoic acid ( EPA ) 1860 mg , docosahexaenoic acid ( DHA ) 1500 mg ] daily form standard prescription strength dose Lovaza™ ( two 1 gram capsule twice daily ) favorable side effect profile potential efficacy demonstrate favorable modulation one blood breast tissue risk biomarkers breast cancer postmenopausal woman .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Inclusion Criteria Subjects must postmenopausal age 25 69 year . Menopause define menstrual period one year intact uterus ovary , woman intact ovary without uterus age 50 , woman estradiol follicle stimulate hormone ( FSH ) postmenopausal range woman ovaries remove . Subjects must increase risk breast cancer basis least one follow criterion : A fiveyear Gail risk ≥ 1.67 % ≥ 2X average risk woman age use either Surveillance Epidemiology End Results ( SEER , http : //seer.cancer.gov ) database , NCI Breast Cancer Risk Assessment Tool ( www.cancer.gov/bcrisktool ) , International Breast Cancer Intervention Study ( IBIS ) Risk Evaluator ( http : //www.emstrials . org/riskevaluator/ ) , tenyear TyrerCuzick model risk 2x population risk . A first degree relative breast cancer age 60 multiple second degree relative breast cancer . Multiple prior biopsy least one prior biopsy exhibit atypical hyperplasia ( AH ) , lobular carcinoma situ ( LCIS ) , ductal carcinoma situ ( DCIS ) . Random periareolar fine needle aspiration ( RPFNA ) evidence hyperplasia atypia within last three year ; Chest neck radiation age 30 ; Mammographic breast density visual estimate equal exceed 50 % . Subjects must willing continue hormonal milieu present baseline throughout trial ( Can start stop type hormone replacement therapy exception vagifem estring ) . Six month must elapse completion prevention intervention trial ( exception weight reduction trial ) , ingestion selective estrogen receptor modulator ( SERM ) aromatase inhibitor ( AI ) prior baseline biomarker assessment . . Subjects history AH , LCIS , ERpositive DCIS diagnostic biopsy , must counsel appropriate standard prevention therapy tamoxifen raloxifene either eligible interested standard prevention therapy . Women DCIS must appropriate local therapy ( lumpectomy plus radiation mastectomy ) . If subject DCIS , least two month must elapse surgery and/or radiation therapy involve breast . Only contralateral ( uninvolved breast ) study RPFNA . The subject may radiation therapy contralateral breast studied Subjects must screen mammogram within 6 month enter interventional portion study read suspicious breast cancer suspicious must complete suggested test include biopsy find evidence cancer . Women must willing offstudy mammogram perform 6 month study entry . Subjects must RPFNA breast within six month prior enter intervention portion study willing another RPFNA ~6.5 month start Lovaza™ . Tissue Eligibility : Subjects must cytomorphologic evidence hyperplasia atypia borderline atypia ( Masood score &gt; 13 ) . There must ≥500 epithelial cell slide cytomorphology . There must sufficient reserve methanolformalin fix material quantitative reverse transcription polymerase chain reaction ( RTqPCR ) . Frozen tissue must also obtain fatty acid analysis , reverse phase proteomics , adipokines cytokine , RTqPCR . Subjects must willing undergo phlebotomy baseline 6 month 6.5 month . Approximately 3 tablespoon blood obtain baseline 6 month 6.5 month 6 tablespoon subject decides participate optional monocyte cytokine release assay . Subjects must produce spot urine sample baseline , 6 month , study conclusion Subjects must willing undergo measurement height , weight , BMI undergo body composite analysis ( DEXA ) initiation conclusion intervention . Subjects must willing complete questionnaire regard diet supplement use , quality life well relevant family history personal health reproductive history medication initiation conclusion intervention . Subjects must willing sign inform consent entire study separate consent repeat RPFNA . Exclusion Criteria Women metastatic malignancy kind . Women prior invasive breast cancer , diagnose treat within past five year . Women currently take anticoagulant . Women breast implant . Women undergone change hormonal milieu past 6 month . Women take omega 3 fatty acid flaxseed supplement within 3 week prior baseline RPFNA woman take high dose omega 3 within past three month . Women regularly take NSAIDS ( &gt; 7 tablet weekly ) . Women take SERM , aromatase inhibitor participate chemoprevention investigational drug study within six month prior baseline RPFNA . Women abnormal renal hepatic function baseline , define blood chemistry value clinically significantly outside normal institutional range . Women history allergy , include hive , fish product . Women BMI 40 kg/m^2 great . Inclusion Women Minorities This study utilizes woman increase risk breast cancer . Subjects recruit establish cohort woman follow Breast Cancer Prevention Center . From previous trial expect 6 % minority accrual similar hospital demographic . Males include due low absolute risk breast cancer , difficulty perform RPFNA male breast .</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>